In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Gene Therapy Superhighway

Executive Summary

Gene Therapy companies need delivery devices for their therapies and device companies must increasingly embrace biotechnologies to improve and differentiate their increasingly commoditized offerings. In a handful of device/biotech deals signed in the pas year, device companies are gaining exclusive worldwide rights to new cardiovascular gene therapies. The next meeting ground for gene therapies and devices: orthobiologics.

Related Content

Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts